Join
Live feed
·
PRReleasevia Quantisnow
ALX Oncology Holdings Inc. logo

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

ByQuantisnow·Wall Street's wire, on your screen.
ALXO· ALX Oncology Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALXO (ALX Oncology Holdings Inc.) and more on Quantisnow.